SG10201804330YA - Engineered high-affinity human t cell receptors - Google Patents
Engineered high-affinity human t cell receptorsInfo
- Publication number
- SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA SG 10201804330Y A SG10201804330Y A SG 10201804330YA
- Authority
- SG
- Singapore
- Prior art keywords
- tcrs
- cell receptors
- affinity
- affinity human
- engineered
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000869 mutational effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907887P | 2013-11-22 | 2013-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201804330YA true SG10201804330YA (en) | 2018-07-30 |
Family
ID=53180203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804335QA SG10201804335QA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
| SG10201804330YA SG10201804330YA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804335QA SG10201804335QA (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10023625B2 (enExample) |
| EP (2) | EP3071594A4 (enExample) |
| JP (4) | JP6476182B2 (enExample) |
| KR (2) | KR102415259B1 (enExample) |
| CN (2) | CN105873945B (enExample) |
| AU (4) | AU2014352826B2 (enExample) |
| BR (1) | BR112016011567A2 (enExample) |
| CA (2) | CA2930847A1 (enExample) |
| DK (1) | DK3071593T3 (enExample) |
| ES (1) | ES2729406T3 (enExample) |
| IL (2) | IL245468B (enExample) |
| MX (3) | MX383471B (enExample) |
| PL (1) | PL3071593T3 (enExample) |
| PT (1) | PT3071593T (enExample) |
| RU (2) | RU2729383C2 (enExample) |
| SA (1) | SA516371174B1 (enExample) |
| SG (2) | SG10201804335QA (enExample) |
| TR (1) | TR201908404T4 (enExample) |
| WO (2) | WO2015077607A1 (enExample) |
| ZA (2) | ZA201603116B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| PL2945647T3 (pl) | 2013-01-15 | 2021-03-08 | Memorial Sloan Kettering Cancer Center | Immunogenne peptydy wt-1 i sposoby ich zastosowania |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| EP3071594A4 (en) | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Engineered high-affinity human t cell receptors |
| CN108601849A (zh) * | 2015-09-22 | 2018-09-28 | 尤利乌斯·马克西米利安维尔茨堡大学 | 一种在淋巴细胞中高水平的和稳定的基因转移的方法 |
| US12364757B2 (en) | 2015-10-01 | 2025-07-22 | Ospedale San Raffaele S.R.L | TCR and uses thereof |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| EP3394092A1 (en) * | 2015-12-23 | 2018-10-31 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| CA3042890A1 (en) | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
| MX2019010972A (es) * | 2017-03-15 | 2019-12-02 | Hutchinson Fred Cancer Res | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. |
| CN110785432B (zh) * | 2017-04-24 | 2024-12-27 | 圣拉斐尔医院有限责任公司 | Tcr和肽 |
| JP7181517B2 (ja) | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| CN112739339B (zh) * | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| WO2020185796A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| CN114555790B (zh) * | 2019-08-20 | 2025-02-25 | 弗雷德哈钦森癌症中心 | Wt-1特异性t细胞免疫疗法 |
| CN115335404A (zh) * | 2020-02-12 | 2022-11-11 | 艾伯维公司 | 双特异性结合分子 |
| KR20230002554A (ko) | 2020-04-28 | 2023-01-05 | 아킬레스 테라퓨틱스 유케이 리미티드 | T 세포 요법 |
| CN112239495B (zh) * | 2020-10-29 | 2022-04-12 | 上海药明生物技术有限公司 | 稳定的tcr结构及应用 |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| WO2022214835A1 (en) | 2021-04-09 | 2022-10-13 | Achilles Therapeutics Uk Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| JP2024524185A (ja) | 2021-06-22 | 2024-07-05 | アキレス セラピューティクス ユーケー リミテッド | 抗原特異的ｔ細胞を生成するための方法 |
| KR20240046834A (ko) * | 2021-07-19 | 2024-04-09 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fanci, rad51, 및 pbk 항원을 표적화하는 펩타이드 및 가공된 t 세포 수용체 및 이의 사용 방법 |
| CN119220425A (zh) * | 2023-07-28 | 2024-12-31 | 佳吾益(北京)科技有限公司 | 发现mhc新抗原肽表位的工程化细胞 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4640561A (en) | 1985-11-15 | 1987-02-03 | Ford Motor Company | Flexible printed circuit connector |
| US5059413A (en) | 1988-04-18 | 1991-10-22 | Xoma Corporation | Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators |
| ATE172879T1 (de) | 1989-08-09 | 1998-11-15 | Rhomed Inc | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5299253A (en) | 1992-04-10 | 1994-03-29 | Akzo N.V. | Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| ATE370967T1 (de) | 1998-10-21 | 2007-09-15 | Altor Bioscience Corp | Polyspezifische bindemoleküle und deren verwendung |
| ATE290020T1 (de) * | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| WO2005113595A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| ATE408684T1 (de) | 2004-05-19 | 2008-10-15 | Medigene Ltd | Verfahren zur verbesserung von t-zellrezeptoren |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| EP2352756B1 (en) * | 2008-11-24 | 2012-09-19 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | High affinity t cell receptor and use thereof |
| WO2010075417A1 (en) * | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| US9409969B2 (en) | 2009-02-09 | 2016-08-09 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| EP2598528A1 (en) * | 2010-07-28 | 2013-06-05 | Immunocore Ltd. | T cell receptors |
| BR112013006718B1 (pt) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| RU2018130123A (ru) * | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
| WO2014191465A1 (en) * | 2013-05-28 | 2014-12-04 | Møller Niels Iversen | Peptides derived from lawsonia intracellularis and their use in vaccination |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| EP3071594A4 (en) | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Engineered high-affinity human t cell receptors |
| WO2016022400A1 (en) | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| CN113105562B (zh) * | 2018-09-26 | 2023-12-01 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii在制备融合蛋白中的应用 |
-
2014
- 2014-11-21 EP EP14864079.0A patent/EP3071594A4/en active Pending
- 2014-11-21 BR BR112016011567A patent/BR112016011567A2/pt not_active Application Discontinuation
- 2014-11-21 RU RU2016124163A patent/RU2729383C2/ru active
- 2014-11-21 US US15/037,476 patent/US10023625B2/en active Active
- 2014-11-21 AU AU2014352826A patent/AU2014352826B2/en active Active
- 2014-11-21 AU AU2014352834A patent/AU2014352834B2/en not_active Ceased
- 2014-11-21 JP JP2016533150A patent/JP6476182B2/ja active Active
- 2014-11-21 RU RU2016124179A patent/RU2740648C2/ru active
- 2014-11-21 KR KR1020167016131A patent/KR102415259B1/ko active Active
- 2014-11-21 WO PCT/US2014/066892 patent/WO2015077607A1/en not_active Ceased
- 2014-11-21 PT PT14863490T patent/PT3071593T/pt unknown
- 2014-11-21 CA CA2930847A patent/CA2930847A1/en not_active Abandoned
- 2014-11-21 PL PL14863490T patent/PL3071593T3/pl unknown
- 2014-11-21 CA CA2930852A patent/CA2930852C/en active Active
- 2014-11-21 MX MX2016006625A patent/MX383471B/es unknown
- 2014-11-21 MX MX2016006620A patent/MX371202B/es active IP Right Grant
- 2014-11-21 DK DK14863490.0T patent/DK3071593T3/da active
- 2014-11-21 SG SG10201804335QA patent/SG10201804335QA/en unknown
- 2014-11-21 US US15/037,485 patent/US10344075B2/en active Active
- 2014-11-21 WO PCT/US2014/066903 patent/WO2015077615A1/en not_active Ceased
- 2014-11-21 JP JP2016533163A patent/JP6697386B2/ja not_active Expired - Fee Related
- 2014-11-21 ES ES14863490T patent/ES2729406T3/es active Active
- 2014-11-21 TR TR2019/08404T patent/TR201908404T4/tr unknown
- 2014-11-21 KR KR1020167016132A patent/KR20160085345A/ko not_active Ceased
- 2014-11-21 EP EP14863490.0A patent/EP3071593B1/en active Active
- 2014-11-21 CN CN201480071620.2A patent/CN105873945B/zh active Active
- 2014-11-21 CN CN201480071635.9A patent/CN105899530B/zh not_active Expired - Fee Related
- 2014-11-21 SG SG10201804330YA patent/SG10201804330YA/en unknown
-
2016
- 2016-05-04 IL IL245468A patent/IL245468B/en active IP Right Grant
- 2016-05-04 IL IL245467A patent/IL245467B/en not_active IP Right Cessation
- 2016-05-10 ZA ZA2016/03116A patent/ZA201603116B/en unknown
- 2016-05-11 ZA ZA2016/03169A patent/ZA201603169B/en unknown
- 2016-05-20 MX MX2021006932A patent/MX2021006932A/es unknown
- 2016-05-21 SA SA516371174A patent/SA516371174B1/ar unknown
-
2018
- 2018-05-25 US US15/990,524 patent/US20190055298A1/en not_active Abandoned
-
2019
- 2019-10-17 JP JP2019190139A patent/JP6970724B2/ja not_active Expired - Fee Related
- 2019-11-28 AU AU2019272003A patent/AU2019272003B2/en not_active Ceased
-
2021
- 2021-04-15 AU AU2021202274A patent/AU2021202274A1/en not_active Abandoned
- 2021-11-01 JP JP2021178468A patent/JP2022023196A/ja active Pending
-
2022
- 2022-01-27 US US17/586,652 patent/US20220396606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201804330YA (en) | Engineered high-affinity human t cell receptors | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| CY1123142T1 (el) | Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων | |
| PH12019502529A1 (en) | Materials and methods for engineering cells and uses thereof in immuno-oncology | |
| AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
| WO2016011210A3 (en) | Engineered cells for adoptive cell therapy | |
| EP4303232A3 (en) | Chimeric antigen receptor and methods of use thereof | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| PH12018501074A1 (en) | Compositions and methods for internalizing enzymes | |
| MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
| HK1255161A1 (zh) | 用於过继性细胞治疗的工程细胞 | |
| MX2021009190A (es) | Conjugados de penetracion celular y metodos de uso de estos. | |
| IN2014DN09787A (enExample) | ||
| EP4292600A3 (en) | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | |
| TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| WO2012021632A3 (en) | Generation and use of pluripotent stem cells | |
| NZ737471A (en) | Hydrophilic linkers for conjugation | |
| EP4275699A3 (en) | Use of the cd2 signaling domain in second-generation chimeric antigen receptors | |
| MX2013014544A (es) | Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia. | |
| WO2013078199A3 (en) | Methods for enhanced in vivo delivery of synthetic, modified rnas | |
| MX2014014337A (es) | Metodo de produccion de alta concentracion de celulas madre. | |
| WO2014122035A3 (en) | Induced dendritic cells and uses thereof | |
| CY1123467T1 (el) | Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1 | |
| IN2015KN00329A (enExample) | ||
| MX2013004062A (es) | Analogos de ciclosporina. |